Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (112)	12/11/2017 1:06:13 PM
From: scaram(o)uche	1 Recommendation Recommended By rkrw Read Replies (1) \| Respond to of 294

car-Ts.... significant expense, antigen-negative relapse. ADCs.... relapse all but guaranteed, have there been CRs? But the major take home, my view, is that 621 has nothing to do with a given antigen or cancer type and has a monotherapy CR under belt. And pseudo-progression is always a good sign, again my view. These are my views, everyone should get their own.

To: tuck who wrote (112)	12/11/2017 11:19:37 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 294

>> Though still good, aren't some other players in the DLBCL space also reporting solid data? << Yes, but that's the way Joe Trader is thinking. What WE are hoping for is the holy grail.... dysfunctional, tumor-resident antigen presenting cells suddenly turning into machines that a Dendrite would admire. It's not looking at DLBCL activity head to head with other agents, it's demonstrated anticancer activity for a new biological paradigm. Maybe. >> The CTCL data looks pretty interesting << Fascinating. >> They really do need a partner. << Too busy revising the thread's header.